<?xml version="1.0" encoding="UTF-8"?>
<ref id="B202-ijms-21-05559">
 <label>202.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Choy</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Freemantle</surname>
    <given-names>N.</given-names>
   </name>
   <name>
    <surname>Proudfoot</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Chen</surname>
    <given-names>C.-I.</given-names>
   </name>
   <name>
    <surname>Pollissard</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Kuznik</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Van Hoogstraten</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Mangan</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Carita</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Huynh</surname>
    <given-names>T.-M.-T.</given-names>
   </name>
  </person-group>
  <article-title>Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor Î± inhibitors: Systematic literature review and network meta-analyses</article-title>
  <source>RMD Open</source>
  <year>2019</year>
  <volume>5</volume>
  <fpage>e000798</fpage>
  <pub-id pub-id-type="doi">10.1136/rmdopen-2018-000798</pub-id>
  <pub-id pub-id-type="pmid">30886733</pub-id>
 </element-citation>
</ref>
